Actithera draws new investors to radiopharma drug pitch
BioPharma Drive: Drug Pricing
JULY 9, 2025
The company is “preparing for clinical development in 2026” across multiple indications, Goutopoulos said. Some of those, including Novartis and Ratio Therapeutics , are also targeting FAP. Actithera has not disclosed which cancers it’s targeting with its therapies.
Let's personalize your content